Document:

Eleventh Amendment to Office Lease

 Exhibit 10.2 
 ELEVENTH AMENDMENT TO OFFICE LEASE 
 This Eleventh Amendment to Office Lease (this
“Eleventh Amendment”) is made and entered into as of April 23, 2009, by and between WA—THREE BELLEVUE CENTER, L.L.C., a Delaware limited liability company (“Landlord”), and INFOSPACE, INC., a Delaware
corporation (“Tenant”). 
 R E C I T A L S : 
 A. Landlord, as successor-in-interest to Three Bellevue Center LLC, a Washington limited liability company, and Tenant, formerly known as InfoSpace.com,
Inc., a Delaware corporation, entered into that certain Office Lease Agreement dated March 10, 2000 (the “Office Lease”), as supplemented by that certain letter dated October 10, 2000, as amended by that certain First
Lease Amendment dated August 1, 2000, and that certain Second Lease Amendment dated August 25, 2000, as supplemented by that certain letter dated May 18, 2001, and that certain letter dated August 31, 2001, as amended by that
certain Third Lease Amendment dated June 4, 2002, and that certain Fourth Lease Amendment dated May 16, 2003, as supplemented by that certain letter dated June 3, 2003, as amended by that certain Fifth Lease Amendment dated
June 23, 2004, as supplemented by that certain letter dated September 1, 2005, and as amended by that certain Sixth Amendment dated September 26, 2005, that certain Seventh Amendment dated April 10, 2006, that certain Eighth
Amendment to Office Lease Agreement, dated September 20, 2007, that certain Ninth Amendment to Office Lease, dated December 21, 2007, and that certain Tenth Amendment to Office Lease, dated January 29, 2008 (collectively, the
“Lease”), pursuant to which Landlord leases to Tenant and Tenant leases from Landlord those certain space (the “Premises”) located in that certain office building located at 601 108th Avenue, N.E., Bellevue,
Washington (“Building”) and commonly known as Key Center. 
 B. The parties desire to amend the Lease on the terms and
conditions set forth in this Eleventh Amendment. 
 AGREEMENT: 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows. 
 1. Defined Terms. Except as
explicitly set forth in this Eleventh Amendment, each initially capitalized term when used herein shall have the same respective meaning as is set forth in the Lease. 

 2. Deletions; Acknowledgements. Effective as of the date hereof, Section V(G) of Exhibit D
to the Office Lease and Section X (Rooftop Equipment) of Exhibit E of the Office Lease are hereby deleted in their entirety and are of no further force or effect. Further, notwithstanding anything contained in the Lease or any other prior agreement
between the parties to the contrary, Tenant hereby acknowledges and agrees that Tenant shall have no further rights (i) with respect to any areas located on the B level of the Building, the penthouse level of the Building, or the rooftop of the
Building (other than the roof area utilized under Section III of Exhibit E to the Office Lease for the Dish/Antenna servicing the Premises) (whether specifically addressed in the Lease or otherwise previously utilized by Tenant), or (ii) to
install or maintain any generator, cooling tower, ups system (outside the Premises) or rooftop equipment (other than the Dish/Antenna). Based upon the terms of this Section 2, the areas relinquished by Tenant and in connection with which
Tenant shall have no further rights (the “Released Areas”) are the “UPS System Area”, the “Generator Area”, the “Roof Space”, and the “Water Treatment System Area”, all as more particularly
set forth on Exhibit A, attached hereto. In connection with the foregoing, Landlord hereby agrees that Tenant shall have no obligation to pay to Landlord any storage or comparable rent or other amounts for the Released Areas, nor shall
Tenant have any other obligations with respect to the Released Areas, in all events to the extent the same relate to the period following the date of this Eleventh Amendment (provided that nothing contained herein shall alter Tenant’s liability
for all obligations with respect to the Released Areas to the extent that same relate to the period prior to the date of this Eleventh Amendment). 
 3. Equipment. Tenant hereby represents and warrants to Landlord that Tenant has transferred all of Tenant’s right, title and interest in all personal property and equipment located in or servicing the Released Areas,
including all cabling and related facilities owned by Tenant (collectively, “Equipment”) to Motricity, Inc., a Delaware corporation. Based upon the foregoing, Landlord and Tenant hereby acknowledge and agree that, notwithstanding
anything in Section VIII or Section XXX of the Office Lease to the contrary, Tenant shall have no obligation to remove the Equipment. 
 4. Storage Space. Landlord and Tenant hereby acknowledge and agree that (i) the “Storage Space” leased by Tenant and that Tenant shall continue to lease pursuant to the terms of Section V of Exhibit E to the
Office Lease consists, collectively, of 1,421 square feet of space known as unit A-114 and 518 square feet of space known as unit A-115 and located on the A level of the Building, designated as the “Storage Premises” on Exhibit A, attached
hereto, and (ii) Tenant retains no right to lease additional Storage Space pursuant to the terms of the Lease. 
 5. No Other
Modifications. Except as otherwise provided herein, all other terms and provisions of the Lease shall remain in full force and effect, unmodified by this Eleventh Amendment. 
 6. Counterparts. This Eleventh Amendment may be executed in any number of original counterparts. Any such counterpart, when executed, shall
constitute an original of this Eleventh Amendment, and all such counterparts together shall constitute one and the same Eleventh Amendment. 
 7. Conflict. In the event of any conflict between the Lease and this Eleventh Amendment, this Eleventh Amendment shall prevail. 
  

 -2- 

 IN WITNESS WHEREOF, the parties have entered into this Eleventh Amendment as of the date first set forth
above. 
  

			
	“LANDLORD”:
	
	WA—THREE BELLEVUE CENTER, L.L.C.,
	a Delaware limited liability company
		
	By:	 	/s/ Jeremy B. Fletcher
		 	Jeremy B. Fletcher,
		 	Senior Managing Director
	
	“TENANT”:
	
	INFOSPACE, INC., a Delaware corporation
		
	By:	 	/s/ David Binder
	Its:	 	CFO
		
	By:	 	/s/ William J. Lansing
	Its:	 	President and CEO

  

 -3- 

 NOTARY PAGES 
  

					
	STATE OF WASHINGTON	  	)	  	
		  	)	  	ss.
	COUNTY OF KING	  	)	  	

 I certify that I know or have satisfactory evidence that David Binder is the person who
appeared before me, and said person acknowledged that (he/she) signed this instrument, on oath stated that (he/she) was authorized to execute the instrument and acknowledged it as the CFO of Infospace, Inc., a
Delaware corporation, to be the free and voluntary act of such party for the uses and purposes mentioned in the instrument. 
  

			
	Dated: 4-27-09
	
	/s/ Cindy Bouldin
	(Signature)
	
	(Seal or stamp)
		
	Title:	 	Notary Public
	
	Notary Public in and for the State of Washington
	
	My appointment expires: 4-4-2010

  

			
	STATE OF WASHINGTON	  	)
		  	) ss.
	COUNTY OF KING	  	)

 I certify that I know or have satisfactory evidence that William Lansing is the person who
appeared before me, and said person acknowledged that (he/she) signed this instrument, on oath stated that (he/she) was authorized to execute the instrument and acknowledged it as the Pres & CEO of
Infospace, Inc., a Delaware corporation, to be the free and voluntary act of such party for the uses and purposes mentioned in the instrument. 
  

			
	Dated: 4-27-09
	
	/s/ Cindy Bouldin
	(Signature)
	
	(Seal or stamp)
		
	Title:	 	Notary Public
	
	Notary Public in and for the State of Washington
	
	My appointment expires: 4-4-2010

  

 -4- 

			
	STATE OF CALIFORNIA	  	)
		  	)
	COUNTY OF LOS ANGELES	  	)

 On April 24, 2009, before me, Elicia A. Hauschild, a Notary Public, personally appeared Jeremy B.
Fletcher, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the
instrument the person, or the entity upon behalf of which the person acted, executed the instrument. 
 I certify under PENALTY OF PERJURY
under the laws of the State of California that the forgoing paragraph is true and correct. 
 WITNESS my hand and official seal. 

 

					
			
	Signature	 	/s/ Elicia A. Hauschild	 	(Seal)
		 		 	

  

 -5- 

 EXHIBIT A 
 LOCATION OF RELEASED AREAS 
  

 EXHIBIT A 
 -1-2009 Executive Officer Compensation Arrangements

 Exhibit 10.84 
 2009 Executive Officer Compensation Arrangements 
  

			
	 Executive Officer
	  	2009 Base Salary
Rate ($)
	 Bruce C. Cozadd
Chairman and Chief Executive Officer
	  	421,200
	 Samuel R. Saks, M.D. (1)
Former Chief
Executive Officer
	  	421,200
	 Robert M. Myers
President
	  	399,600
	 Carol A. Gamble
Senior Vice President, General Counsel and Corporate Secretary
	  	339,150
	 Janne L. T. Wissel
Senior Vice President and Chief Regulatory Officer
	  	321,300
	 Joan E. Colligan
Principal Accounting Officer and Acting Principal Financial Officer
	  	210,000

  

	 (1)
	 Dr. Saks resigned his position with the company effective April 3, 2009 and has not received any compensation
since that date. Dr. Saks executed a consulting agreement with us effective April 4, 2009 through April 3, 2010, but to date has not performed any consulting for us pursuant to that agreement.Consulting Agreement - Samuel R. Saks, MD

 Exhibit 10.85 
 April 3, 2009 
 Samuel R. Saks, MD 
 Dear
Dr. Saks: 
 The purpose of this Letter Agreement (the “Agreement”) is to set forth the terms of the consultancy with Jazz Pharmaceuticals,
Inc. with a principal place of business at 3180 Porter Drive, Palo Alto, CA 94304 (together with its subsidiaries, “Jazz Pharmaceuticals”), by Samuel R. Saks, MD (“Consultant”) with a principal place of business at 2404 Hillside
Drive, Burlingame, CA 94010, which are as follows: 
 1. Consultant will act as a consultant to Jazz Pharmaceuticals from time to time during
the period from April 4, 2009 to April 3, 2010, or longer if mutually agreed to in writing by the parties, unless this Agreement is earlier terminated by either parties in accordance with the terms of this Agreement. 
 2. We plan to consult with you on clinical, medical and other matters as such relate to activities of Jazz Pharmaceuticals. The consultancy will be in
the form of meetings, advice, and the like, at facilities of Jazz Pharmaceuticals or at other mutually convenient locations as will be agreed to by the parties in advance. Consultant will use his diligent efforts to perform all services hereunder in
accordance with agreed upon timetables. 
 3. In recognition of these services, Jazz Pharmaceuticals agrees to compensate Consultant at the
rate of $375 per full hour of consulting time (exclusive of travel time), prorated for partial hours, plus reasonable documented out-of-pocket expenses incurred in connection with such consulting services and consistent with Jazz
Pharmaceuticals’ reimbursement policies. Consultant will invoice Jazz Pharmaceuticals not more frequently than monthly and such undisputed invoices will be payable 30 days after receipt by Jazz Pharmaceuticals. Payment for consulting services
rendered hereunder and related expenses will be subject to the completion and documentation, if applicable, of such services to the reasonable satisfaction of Jazz Pharmaceuticals. 
 4. “Confidential Information” means (i) all information, including without limitation data, technology, samples and specimens relating to
Jazz Pharmaceuticals and its products, product concepts, technologies, businesses, financial, sales, marketing, clinical or regulatory affairs, manufacturing processes and procedures, or those of any third party from whom Jazz Pharmaceuticals
receives information on a confidential basis, whether written, graphic or oral, furnished to Consultant by or on behalf of Jazz Pharmaceuticals, either directly or indirectly, or obtained or observed by Consultant, and (ii) the services to be
provided by Consultant hereunder, with the exception only of the following: 
  

	 	a)	information that is now in the public domain or subsequently enters the public domain without fault on the part of Consultant; 

 Samuel R. Saks, MD 
 April 3, 2009 
 Page 2 of 5 
  

	 	b)	information that is presently known by Consultant from Consultant’s own sources without restriction as evidenced by Consultant’s prior written records; and

  

	 	c)	information disclosed to Consultant without restriction by a third party legally and contractually entitled to make such disclosures without restriction. 

Any combination of features or disclosures will not be deemed to fall within the foregoing exclusions merely because certain individual features are published or
available to the general public or in the rightful possession of Consultant unless the combination as a whole falls within any of the above exceptions. 
 Except as required in Consultant’s duties to Jazz Pharmaceuticals, Consultant agrees not to disclose or use at any time or for any purpose, either during or subsequent to the term of this Agreement, any Confidential Information,
without the prior written consent of Jazz Pharmaceuticals, to be given or withheld in Jazz Pharmaceuticals’ absolute discretion. Consultant will take all necessary and reasonable precautions to prevent the disclosure of Confidential Information
to any unauthorized third parties. 
 Notwithstanding the foregoing, Confidential Information may be disclosed to the extent required by applicable laws or
regulations or as ordered by a court or other regulatory body having competent jurisdiction provided that Consultant uses his best efforts to limit the disclosure and maintain confidentiality to the extent possible and provides reasonable prior
written notice to Jazz Pharmaceuticals. 
 Consultant acknowledges that the use or disclosure of Confidential Information without Jazz Pharmaceuticals’
express written permission will cause Jazz Pharmaceuticals irreparable harm and that any material breach or threatened material breach of this Agreement by Consultant will entitle Jazz Pharmaceuticals to seek injunctive relief and reasonable
attorneys’ fees, in addition to any other legal remedies available to it, in any court of competent jurisdiction. 
 5. All inventions,
ideas, improvements, discoveries, enhancements, modifications, know-how, trade secrets, data, information and intellectual property rights of every kind and description conceived, generated, made, fixed in a tangible medium of expression or reduced
to practice, as the case may be, by Consultant, either alone or jointly with others, which arise out of or relate to this Agreement (the “Intellectual 

  

 Samuel R. Saks, MD 
 April 3, 2009 
 Page 3 of 5 
  
 
Property”) will be the sole and exclusive property of Jazz Pharmaceuticals. Consultant agrees to disclose such Intellectual Property promptly to Jazz
Pharmaceuticals, to assign all of Consultant’s right, title and interest in and to any such Intellectual Property promptly to Jazz Pharmaceuticals without royalty or any other consideration and to execute all applications, assignments or other
instruments reasonably requested by Jazz Pharmaceuticals, in order for Jazz Pharmaceuticals to establish Jazz Pharmaceuticals’ ownership of such Intellectual Property and to obtain whatever protection for such Intellectual Property, including
patent and copyright rights, in any and all countries on such Intellectual Property as Jazz Pharmaceuticals will determine. Consultant further agrees to cooperate fully with Jazz Pharmaceuticals in the process of securing and enforcing Jazz
Pharmaceuticals’ rights to such Intellectual Property and Jazz Pharmaceuticals will compensate Consultant for Consultant’s reasonable time devoted to such activities at Jazz Pharmaceuticals’ request and reimburse Consultant for
reasonable expenses incurred in connection therewith. Consultant hereby irrevocably designates and appoints Jazz Pharmaceuticals as his agents and attorneys-in-fact to act for and in Consultant’s behalf to execute and file any document and to
do all other lawfully permitted acts to further the foregoing with the same legal force and effect as if executed by Jazz Pharmaceuticals. If any part of the services performed in accordance with this Agreement or Intellectual Property is based on,
incorporates or is an improvement or derivative of, or cannot be reasonably and fully made, used, reproduced, modified, distributed or otherwise exploited without using or violating, any technology or intellectual property rights owned or licensed
by Consultant and not assigned hereunder, then Consultant hereby grants and agrees to grant to Jazz Pharmaceuticals and its affiliates and successors a nonexclusive, perpetual, irrevocable, worldwide, royalty-free, sublicensable right and license to
exploit and exercise all such technology and intellectual property rights in support of Jazz Pharmaceuticals’ exercise or exploitation of the services, Intellectual Property, other work performed hereunder, or any assigned rights (including any
modifications, improvements and derivatives of any of them). 
 6. All Confidential Information disclosed by or on behalf of Jazz
Pharmaceuticals to Consultant pursuant to this Agreement will be and remain the property of Jazz Pharmaceuticals and all written Confidential Information and copies thereof will be promptly returned or lawfully destroyed upon the earlier of the
termination of this Agreement or Jazz Pharmaceuticals’ request, provided that Consultant will be entitled to retain one set of all such information for the sole purpose of monitoring Consultant’s obligations hereunder. 
 7. It is understood that Consultant will be serving under this Agreement as an independent contractor, and will not be eligible to participate in any
benefits extended by Jazz Pharmaceuticals to its employees. As an independent contractor, Consultant is solely responsible for all taxes, withholdings, and other statutory or contractual obligations of any sort, including, but not limited to,
workers’ compensation insurance. Consultant agrees to defend, indemnify and hold Jazz Pharmaceuticals harmless from any and all claims, damages, liabilities, losses, attorneys’ fees and expenses on account of (a) an alleged failure by
Consultant to satisfy any such obligations or any other obligation (under this Agreement or otherwise) or (b) any other action or inaction of Consultant. 
  

 Samuel R. Saks, MD 
 April 3, 2009 
 Page 4 of 5 
  
 8. Consultant represents and warrants to Jazz Pharmaceuticals that: (i) Consultant is legally able to enter into this
consulting arrangement with Jazz Pharmaceuticals and that this Agreement will not and does not conflict with any agreement, arrangement or understanding, written or oral, to which Consultant is a party or by which Consultant is bound, (ii) the
services performed by the Consultant pursuant to this Agreement will be performed in a professional and workmanlike manner, (iii) all work under this Agreement will be Consultant’s original work and none of the services or Intellectual
Property or any development, use, production, distribution or exploitation thereof will infringe, misappropriate or violate any intellectual property or other right of any person or entity (including, without limitation, Consultant himself),
(iv) Consultant will not disclose to Jazz Pharmaceuticals or use for its benefit any trade secret or proprietary or confidential information of any third party; and (v) Consultant agrees to disclose to any committee that Consultant is a
member of and which sets formularies or develops clinical guidelines the nature and existence of Consultant’s relationship with Jazz Pharmaceuticals. 
 9. Consultant represents and warrants to Jazz Pharmaceuticals that he (i) is not currently excluded, debarred, suspended or otherwise ineligible to participate in the Federal health care programs or in Federal
procurement or nonprocurement programs or is proposed for exclusion under such programs, and (ii) has not been convicted of a criminal offense that falls within the ambits of 42 U.S.C. §1320a-(7)a or §1320a-7(b)(1)-(3) but has
not yet been excluded, debarred, suspended, or otherwise declared ineligible to participate in the Federal health care programs or in federal procurement or nonprocurement programs. Consultant agrees that he will immediately notify Jazz
Pharmaceuticals in writing if any of the representations and warranties made by Consultant in this Paragraph 9 cease to be true at any time during the term of this Agreement. 
 10. Consultant agrees that during the term of this Agreement and for one year thereafter, Consultant will not solicit or in any manner
encourage any employee of Jazz Pharmaceuticals to leave its employ. 
 11. Either party may terminate this Agreement at any time upon 30
days’ written notice to the other party. The provisions of Paragraphs 4 through 11 of this Agreement, and any remedies for breach of this Agreement, will survive expiration or termination of this Agreement for any reason. In the event of
termination by Jazz Pharmaceuticals, subject to Paragraph 3, Consultant will be entitled to compensation for services rendered and reimbursement for noncancellable expenses incurred under this Agreement prior to the date of termination.

 12. Any notice required or permitted to be given hereunder will be effective upon receipt and will be given in writing, in English and
delivered in person, via established express courier service (with confirmation of receipt), confirmed facsimile or registered or certified mail, postage prepaid, return receipt requested, to the parties at their respective addresses given herein or
at such other address designated by written notice. 

 Samuel R. Saks, MD 
 April 3, 2009 
 Page 5 of 5 
  
 13. This Agreement and the performance contemplated hereunder are personal to Consultant and Consultant will not have the
right or ability to subcontract, delegate, assign or otherwise transfer any rights or obligations under this Agreement without the prior written consent of Jazz Pharmaceuticals. This Agreement will be binding upon, and inure to the benefit of, the
successors, representatives and permitted assigns of the parties. 
 14. This Agreement will be governed and construed in accordance with the
laws of the State of California, excluding any choice of law rules which may direct the application of the laws of another jurisdiction. 
 If the foregoing
is acceptable, please execute both copies of this Agreement and return one fully executed original to Jazz Pharmaceuticals. 
  

	
	Very truly yours,
	
	Jazz Pharmaceuticals, Inc.
	
	/s/ Carol Gamble
	Carol Gamble
	Senior Vice President and General Counsel
	
	Agreed to and accepted this 3rd day of April, 2009.
	
	/s/ Samuel R. Saks, MD
	Samuel R. Saks, MD

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]